Hemostasis Today

September, 2026
September 2026
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
William Pao: Celebrating a Landmark Breakthrough in Hemophilia Care
Sep 10, 2026, 11:56

William Pao: Celebrating a Landmark Breakthrough in Hemophilia Care

William Pao, Adjunct Professor of Pharmacology and Medicine at Joan and Sanford I. Weill Medical College of Cornell University, Chief Executive Officer at Revelio Therapeutics, shared a post on LinkedIn about a recent article by him, published in PNAS, adding:

“Please join me in wishing congratulations to Kunihiro Hattori, Takehisa Kitazawa and Tomoyuki Igawa from Chugai Pharmaceutical Co., Ltd.!

They have just been awarded by The Albert and Mary Lasker Foundation the 2026 Lasker-Debakey Clinical Medical Research Award for invention of a bispecific antibody that joins blood clotting Factors IXa (FIXa) and X (FX), restoring deficient Factor VIII (FVIII) activity in patients with hemophilia A and preventing severe bleeding in this hereditary disorder.

Over the span of 10 years, starting in 2000, Hattori – a molecular and hematology biologist, Kitazawa – a hematology biologist and translational researcher, and Igawa – a biochemist and protein engineer, conceived, designed and created emicizumab, a novel FVIII-mimetic.

Their collective research efforts demonstrate how imagination, determination and multidisciplinary scientific research come together to improve patients’ lives.

Their journey highlights what it takes to make true first-in-class breakthrough medicines for patients.”

Stay updated with Hemostasis Today.